Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Date:4/15/2008

- 80% of Subjects Immunized with Anti-PS Immunocytokines and Irradiated Tumor Cells Achieved Long-Term Survival Compared to Just 20% of Controls -

- Data Highlights Broad Anti-Cancer Potential of Peregrine's Anti-PS

Vascular Targeting Antibodies -

SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that a preclinical study presented yesterday at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) demonstrates the vaccine-like ability of immunocytokine proteins combining its anti-phosphatidylserine (anti-PS) antibodies and cytokines such as IL-2 to generate robust and protective immune responses in a highly aggressive cancer model. Dr. Xianming Huang, assistant professor of pharmacology, and colleagues at the University of Texas Southwestern Medical Center at Dallas presented their findings from a study in mice assessing the efficacy of a tumor vaccine approach that uses these anti-PS immunocytokines in combination with radiation to achieve immunity to a lethal form of breast cancer.

Dr. Huang commented, "A likely contributor to the lack of immunogenicity of tumors is the fact that phosphatidylserine (PS) expressed on the surface of some cancer cells acts to dampen the body's normal immune response. By coating cancer cells with our anti-PS immunocytokines and then irradiating them to up-regulate the expression of the PS target, we were able to block the immunosuppressive effect of the PS. This enabled the pre-treated animals to leverage the T-cell activating effects of the IL-2 in the immunocytokine to mount a robust and sustained immune response to this unusually aggressive cancer."

In the study
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
7. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
8. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading developer ... it,will hold its 2010 Annual Meeting of Shareholders on Thursday, ... meeting will be held concurrently at No. 39,Shangdi Xi Road, Haidian ... St.,John,s, Antigua . All shareholders of record as of ...
... WASHINGTON , June 17 The chairman of ... the U.S. Food and Drug Administration (FDA) over its move toward ... "emergency contraceptive." In a June 17 letter to Dr. ... DiNardo of Galveston - Houston criticized the FDA,s ...
Cached Medicine Technology:Sinovac Schedules 2010 Annual Meeting of Shareholders 2Sinovac Schedules 2010 Annual Meeting of Shareholders 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 2Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 4
(Date:4/24/2014)... Scientists from The University of Manchester have identified a ... them more open to treatment. , The study published ... way for the development of drugs to target cells ... team made the discovery whilst exploring the possible mechanisms ... to treat breast and colon cancer. , Dr Andrew ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to ... slices and kale chips. The more likely culprits include ... , Unfortunately for children who play youth baseball, ... contributing to weight problems, according to researchers at Wake ... current online edition of Childhood Obesity , found ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... theory that contemporary orgasms succor fertility found that women who ... than those that did not. The best way to get ... scientists have ascertained. ,Dr Cathy, from the School of ... age of 32. //The women were asked to go to ...
... sexual intercorse soon after delivery could jeopardize their lives. A ... occured because they indulged in sexual intercourse too soon after ... air embolisms, traveling to the heart and brain.The blood vessels ... upto 4 weeks to return to normal after birth. The ...
... females who are given a choice to select their partners ... research involves the humble fruit fly, but experts believe it ... from the University of Georgia, led by Dr Daniel Promislow, ... in a vial with one virgin female.// Some of the ...
... AIDS will surpass the Black Death as the world's worst ... AIDS do not get life prolonging drugs. The illness has ... 14,000 people are infected each day with HIV, which destroys ... living with AIDS will die, pushing the death toll beyond ...
... out a high number of operations have lower deaths rates ... a scientist at the Institute of Public Health in Cambridge, ... 12 hospitals carrying// out heart surgery on children from 1991 ... carrying out 120 open heart operations on children less than ...
... of countries where leprosy is still a health problem need ... curable disease, the World Health Organization (WHO) has said. Partners ... meeting in Brazil for their annual meeting. Brazil is one ... major public health issue. The others are India, Madagascar, Mozambique, ...
Cached Medicine News:
... a biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) ... native cornea., ,The World Health Organisation (WHO) ... 10 million people worldwide, however only 100,000 ... shortfall is due to a combination of ...
PDA application providing complex evaluation and management coding rule interactive templates....
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the leading portable drug reference....
Medicine Products: